Comparative Pharmacology
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus PERTOFRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus PERTOFRANE.
AMITRIPTYLINE HYDROCHLORIDE vs PERTOFRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
150-300 mg oral in divided doses per day; 75-150 mg IM in divided doses per day
None Documented
None Documented
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Terminal elimination half-life is 14–21 hours. Steady-state is reached within 5–7 days. The half-life is prolonged in elderly and patients with hepatic impairment.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Primarily renal (70%), with 30% as unchanged drug; remainder as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant